Quantum-Si (NASDAQ:QSI) Insider John Vieceli Sells 15,112 Shares of Stock

Quantum-Si Incorporated (NASDAQ:QSI) insider John Vieceli sold 15,112 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $0.90, for a total value of $13,600.80. Following the transaction, the insider owned 1,140,434 shares of the company’s stock, valued at approximately $1,026,390.60. This represents a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Quantum-Si Price Performance

QSI opened at $0.83 on Thursday. Quantum-Si Incorporated has a 12 month low of $0.69 and a 12 month high of $3.10. The stock has a market cap of $180.13 million, a P/E ratio of -1.62 and a beta of 3.18. The stock’s 50 day moving average price is $0.99 and its 200 day moving average price is $1.04.

Quantum-Si (NASDAQ:QSI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%.The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Equities analysts anticipate that Quantum-Si Incorporated will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Quantum-Si

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. raised its stake in shares of Quantum-Si by 177.7% in the 1st quarter. Invesco Ltd. now owns 103,657 shares of the company’s stock worth $124,000 after buying an additional 66,336 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Quantum-Si by 23.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock valued at $85,000 after buying an additional 13,546 shares in the last quarter. Millennium Management LLC bought a new position in Quantum-Si during the first quarter valued at about $4,721,000. JPMorgan Chase & Co. grew its holdings in Quantum-Si by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock worth $131,000 after acquiring an additional 9,005 shares during the period. Finally, Rhumbline Advisers grew its holdings in Quantum-Si by 36.0% during the second quarter. Rhumbline Advisers now owns 203,967 shares of the company’s stock worth $400,000 after acquiring an additional 53,994 shares during the period. 39.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on QSI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group dropped their price target on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Quantum-Si presently has a consensus rating of “Reduce” and an average target price of $1.00.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.